BioStock Studio: DanCann Pharma about the road to commercial breakthrough

DanCann Pharma is active within a growing field of drug development – medical cannabis and therapeutic cannabinoids. The goal is to provide patients in a spectrum of disease indications with safe treatment options without them having to turn to the black market. According to the company, it is facing its commercial breakthrough and to finance the way forward, it is now carrying out an issue of 28.5 million DKK. CEO Jeppe Krog Rasmussen visited BioStock’s studio to tell us more.

See the interview at biostock.se:

https://www.biostock.se/en/2022/11/dancann-pharma-about-the-road-to-commercial-breakthrough/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/